A phase I trial is evaluating the antitumour activity and safety profile of patritumab deruxtecan, an HER3 antibody, in EGFR-mutant NSCLC patients progressing to a prior EGFR TKI and platinum-based chemotherapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.